Ranbaxy gains on Prilosec generic

Ranbaxy Laboratories got a welcome dose of good news as its shares climbed more than 3 percent on the launch of its generic version of the acid reflux drug Prilosec in the U.S., under an agreement with AstraZeneca. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.